Sientra (SIEN) Received its Third Buy in a Row

After Canaccord Genuity and Colliers Securities gave Sientra (NASDAQ: SIEN) a Buy rating last month, the company received another Buy, this time from Leerink Partners. Analyst Richard Newitter maintained a Buy rating on Sientra today and set a price target of $10.00. The company’s shares closed last Friday at $7.22.

According to TipRanks.com, Newitter is a 5-star analyst with an average return of 27.7% and a 71.9% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Itamar Medical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sientra with a $9.33 average price target, which is a 35.4% upside from current levels. In a report released today, Colliers Securities also reiterated a Buy rating on the stock with a $8.00 price target.

See today’s analyst top recommended stocks >>

Sientra’s market cap is currently $421.2M and has a P/E ratio of -4.30. The company has a Price to Book ratio of -483.23.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SIEN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini in August 29, 2003 and is headquartered in Santa Barbara, CA.